The U.S. federal government's "covid.gov" website now redirects to a White House page offering up the unproven theory that ...

Shares of Novavax Inc. NVAX shed 3.23% to $6.00 Thursday, on what proved to be an all-around dismal trading session for the ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Novavax (NVAX – Research Report) today and set a price target of ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.